5. Conclusions
In conclusion, we found that disparities in reporting and participation
of minority racial groups continue to exist. We believe that requiring
reporting of patient demographic data in clinical trials, in compliance
with the NIH Revitalization Act, will improve transparency and the rate
of reporting. Furthermore, it will critically inform health policy
makers and other stakeholders to address the root causes of
underrepresentation of minorities by addressing social barriers and
hesitancy to participate in clinical trials [19].